Wanbang Biopharma has established a domestic first-class R&D and manufacturing site for genetic engineering drugs of prokaryotic and eukaryotic cells. The research and development of recombinant human insulin and insulin analogues, recombinant human erythropoietin and other recombinant protein drugs take the leading position in China market. Through equity participation, Wanbang Biopharma has established a R&D laboratory of small molecule innovative drugs in San Francisco, USA, which is also in the leading position in the field of small molecule and high-difficulty generic drugs development. The company invests around 10% of the sales revenues for new product research and development annually; it has a professional R&D team with over 300 personnel, more than 38% with high education-level including masters or PhDs, and applies for more than 40 national patents annually, and launches several new products into market.
Currently Wanbang Biopharma holds 20 subsidiaries and has established more than 9 manufacturing sites across China, total area of which is more than 167 acres.